Traders should monitor for potential downward pressure on CNTA shares, especially if this selling follows weak clinical data, lack of near-term catalysts, or broader biotech sector weakness. Assess whether this is part of a routine post-vesting disposition or a signal of deteriorating confidence.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 16 $28.29entry
- T+1 · 8mo ago +2.33%α +2.07% · $28.95
- T+5 · 8mo ago −8.31%α −6.27% · $25.94
- T+20 · 7mo ago +39.94%α +36.14% · $39.59
- T+60 · 5mo ago +40.30%α +31.87% · $39.69
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Centessa Pharmaceuticals insiders executed a significant share disposition cluster within one day, led by the Chief People Officer selling $2.82M in shares and exercising derivatives, alongside the Chief Business Officer selling $1.6M. The total open-market sales amount to $4.43M, representing a notable insider selling event.
Key Financial Metrics
Key Facts
- Chief People Officer Karen M. Anderson sold 107,961 shares for $2,823,234 in open-market transactions.
- Anderson also exercised derivative securities involving 218,796 shares with a total cost basis of $438,686, resulting in no cash inflow for the company.
- Chief Business Officer Gregory M. Weinhoff sold 61,253 shares for $1,602,795 in open-market transactions.
- Total open-market proceeds from insider sales: $4,426,029 over a single day.
Financial Impact
$4.43M in open-market insider sales over one day, representing ~0.11% of Centessa's $3.9B market cap
Risk Factors
- Insider selling may signal lack of confidence in near-term prospects, particularly from C-suite executives.
- Risk of negative market perception amplifying selling pressure, especially in a volatile biotech environment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (4 trades, 7d window) | cluster-CNTA-1773440631845 |
Track record
5 reports on CNTA
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +8.31% at T+5 after the Mar 13, 2026 report. 3 of 3 went positive at some point.
Filters
- Jul 6, 202619w ago 15-12G Bearish 7/10 No price data
- Apr 17, 202630w ago PREM14A Bullish 9/10 Entry $39.51 to $39.51 · 0.00% −0.91% vs SPY
- Apr 13, 202631w ago DEFA14A Bullish 8/10 Entry $39.59 to $39.49 ▼ −0.25% −1.65% vs SPY
- Mar 13, 202635w ago Insider Cluster Bearish 7/10 Entry $28.29 to $25.94 ▲ +8.31% +6.27% vs SPY
- Mar 13, 202635w ago Insider Cluster Bearish 6/10 Viewing Entry $28.29 to $25.94 ▲ +8.31% +6.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers